

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on June 17 2000

FULBRIGHT & JAWORSKI L.L.P.

By Donnamaria Perkins
Donnamaria Perkins



P#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : JAGER, et al.

Serial No. : 09/451,739

Filed : November 30, 1999

For : ISOLATED NUCLEIC ACID MOLECULES ENCODING
CANCER ASSOCIATED ANTIGENS, THE ANTIGENS
PER SE, AND USES THEREOF

Group Art Unit : 1643

Examiner : Not Assigned

June 27, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

RECEIVED
JUL 16 2000

**INFORMATION
DISCLOSURE
STATEMENT**
(37 CFR §1.56, §1.97)

RECEIVED
JUL 15 2000

Sir:

TECH CENTER 1600/2900

Applicants wish to make the attached reference of record in this application. It is not prior art, but sets forth information that is also set out in this application.

Jäger, et al, "Cancer-Testis Antigens and ING1 Tumor Suppressor Gene Product Are Breast Cancer Antigens: Characterization of Tissue-specific ING1 Transcripts and a Homologue Gene," Canc. Res. 59:6197-6204 (December 15, 1999).

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 

Norman D. Hanson

Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000